Search

As Novartis Buys In to Gene Therapy, GSK Bows Out with Orchard Deal

AS NOVARTIS BUYS IN TO GENE THERAPY, GSK BOWS OUT WITH ORCHARD DEAL

Novartis just bet close to $9 billion on the future of gene therapy, a boost for a field that hasn't yet seen commercial success. In...

 
 
 

DERMAVANT HIRES CSO FROM GLAXOSMITHKLINE, BUYS IN EXCESSIVE SWEATING DRUG

Dermavant Sciences has lured David Rubenstein, M.D., Ph.D., away from GlaxoSmithKline to serve as its CSO. The Roivant company unveiled...

Bio Roundup: Biotech IPOs, Migraine Progress, Takeda Woos Shire & More

BIO ROUNDUP: BIOTECH IPOS, MIGRAINE PROGRESS, TAKEDA WOOS SHIRE & MORE

If the recent IPO activity seems to be on overdrive, it's not your imagination. The number of companies filing to go public in the...

 
 
 
GSK announces ‘strategic review' of consumer nutrition portfolio to help fund €13bn Novartis deal

GSK ANNOUNCES ‘STRATEGIC REVIEW' OF CONSUMER NUTRITION PORTFOLIO TO HELP FUND €13BN NOVARTIS DEAL

GlaxoSmithKline could look to sell some â or all â of its nutrition portfolio to help fund the â10.5 billion acquisition of Novartisâ...

Bio Roundup: DIY Biohacking, PCSK9 Data, Solid Setback & More

BIO ROUNDUP: DIY BIOHACKING, PCSK9 DATA, SOLID SETBACK & MORE

Drug prices are top of mind for many patients. Some of them have to cut back on basic needs just to pay for treatments that seem to...

 
 
 
 
 
 
 
 
 

POACHED FROM ASTRAZENECA, NEW PHARMA HEAD LOOKS TO RESUSCITATE GLAXOSMITHKLINE'S CANCER PIPELINE

GlaxoSmithKline will scout for deal opportunities in cancer medicine, as well as immunology, as the drugmaker seeks to rebuild its...

Propeller, Express Scripts Partner to Monitor Asthma, COPD Patients

PROPELLER, EXPRESS SCRIPTS PARTNER TO MONITOR ASTHMA, COPD PATIENTS

Propeller Health, a startup developing Internet-connected inhalers and complementary software to help people with respiratory disease...

 
 
 
Health Policy Career Advice from the Private Sector

HEALTH POLICY CAREER ADVICE FROM THE PRIVATE SECTOR

Duke alum Andrew Barnhill returned to campus to discuss his career path and current responsibilities as the Director of Federal Policy...

 
 
 
No Effect: Axovant Drug Is Latest Casualty In Alzheimer's Battle

NO EFFECT: AXOVANT DRUG IS LATEST CASUALTY IN ALZHEIMER'S BATTLE

Another high-profile attempt to produce an Alzheimer's treatment has failed. An unusual biotech company called Axovant Sciences reported...